Clinical improvement in psoriasis with specific targeting of interleukin-23

• Published in: Nature (London) Vol. 521; no. 7551; pp. 222 - 226
• Main Authors: Kopp, Tamara, Riedl, Elisabeth, Bangert, Christine, Bowman, Edward P., Greisenegger, Elli, Horowitz, Ann, Kittler, Harald, Blumenschein, Wendy M., McClanahan, Terrill K., Marbury, Thomas, Zachariae, Claus, Xu, Danlin, Hou, Xiaoli Shirley, Mehta, Anish, Zandvliet, Anthe S., Montgomery, Diana, van Aarle, Frank, Khalilieh, Sauzanne
• Format: Journal Article
• Language: English
• Published: London Nature Publishing Group UK 14.05.2015; Nature Publishing Group
• Subjects: 13; 38/1; 692/699/249/1313/1758; Adolescent; Adult; Aged; Antibodies, Monoclonal - adverse effects; Antibodies, Monoclonal - immunology; Antibodies, Monoclonal - pharmacology; Antibodies, Monoclonal - therapeutic use; Binding sites; Care and treatment; Cytokines; Double-Blind Method; Epithelium - drug effects; Epithelium - pathology; Gene expression; Gene Expression Regulation - drug effects; Health aspects; Humanities and Social Sciences; Humans; Immunotherapy; Interleukin-23 - antagonists & inhibitors; Interleukin-23 - chemistry; Interleukin-23 - immunology; Interleukins; letter; Ligands; Middle Aged; Molecular Targeted Therapy; multidisciplinary; Patient outcomes; Protein Subunits - antagonists & inhibitors; Protein Subunits - chemistry; Protein Subunits - immunology; Psoriasis; Psoriasis - drug therapy; Psoriasis - immunology; Psoriasis - metabolism; Psoriasis - pathology; Science; Skin - drug effects; Skin - immunology; Skin - metabolism; Skin - pathology; Skin diseases; Studies; Treatment Outcome; Young Adult

A proof-of-concept phase I clinical trial demonstrates that targeting interleukin (IL)-23 with an antibody that binds to the p19 subunit leads to clinical improvement of disease in patients with moderate to severe psoriasis. Antibody treatment of psoriasis Sauzanne Khalilieh and colleagues report a...